View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 26, 2021

Pfizer/BioNTech’s Comirnaty peak forecast sales four times greater than the next competitor

Comirnaty (tozinameran), the world’s first Covid-19 vaccine to be approved, is set to retain its crown as the leading Covid-19 vaccine, with forecast peak sales hugely surpassing other vaccine competitors, Moderna’s mRNA-1273 and Novavax’s NVX-CoV2373.

By GlobalData Healthcare

Comirnaty (tozinameran), the world’s first Covid-19 vaccine to be approved, is set to retain its crown as the leading Covid-19 vaccine, with forecast peak sales hugely surpassing other vaccine competitors, Moderna ’s mRNA-1273 and Novavax ’s NVX-CoV2373.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Currently, the top three Covid-19 vaccines by Q1 2021 global analyst consensus sales forecast peak sales, derived from broker reports, are Moderna ’s mRNA vaccine mRNA-1273, Pfizer/BioNTech SE’s mRNA vaccine Comirnaty, and Novavax ’s subunit vaccine NVX-CoV2373, according to the GlobalData Sales and Forecast database, Pharma Intelligence Center. Out of the top three, Comirnaty has remained the leading Covid-19 vaccine by forecast sales ever since it received Emergency Use Authorization (EUA) from the UK on December 11, 2020, making it the first Covid-19 vaccine approved globally. Since December it has received EUAs in multiple countries, including the US, EU, Australia, Canada, and Switzerland. This, combined with its greater than 90% efficacy against Covid-19 and in vitro studies showing neutralization of the South African variant spike mutations, has ensured that it is considered the gold standard for Covid-19 vaccines.

This can be seen in its peak forecast sales, where according to the latest consensus forecast from GlobalData’s Sales and Forecast database, Pharma Intelligence Center, Comirnaty is expected to make $24.8bn in sales in 2021, an increase of $11bn on the previous Q4 2020 GlobalData global analyst consensus forecast. This is 3.8 times greater than the peak forecast sales of NVX-CoV2373 and 4.6 times greater than mRNA-1273. Comirnaty’s closest competitors by forecast sales, while both are forecast to be blockbusters in their own right, are only forecast to give more moderate peak sales of $5.4bn in 2021 and $7.2bn in 2027 respectively.

Comirnaty peak forecast sales are much greater than main rival mRNA-1273, despite both vaccines using similar mRNA technology, and though mRNA-1273 received its own EUA on December 18, 2020, from the FDA, thus losing out on the status of being the first to market by only seven days. At the same time, mRNA-1273 is easier to transport and store, being able to be shipped at -20°C (-4°F) and stored at that temperature for six months, far easier than Comirnaty, which currently requires ultra-cold storage at -80°C, yet these benefits are not set to bring its sales ahead of Comirnaty. Additionally, Pfizer has recently submitted stability data that could allow Comirnaty to be stored at normal refrigerated temperatures for up to two weeks, reducing that advantage for mRNA-1273.

More vaccines are continuing to enter the market, such as AstraZeneca’s AZD-1222 and Johnson & Johnson’s JNJ-78436735 one-shot Covid–19 vaccines, so while Comirnaty is riding high on the first-to-market benefits, it remains to be seen if this state of affairs will continue and if these high forecast peak sales will materialize.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology